Аннотация
Доступ к центральным венам широко используется современной медициной для решения задач периодического гемодиализа, длительной химиотерапии, парентерального питания и т.д. Основным осложнением, лимитирующим широту и длительность использования центральных катетеров, равно как и имплантируемых устройств (портов), является их контаминация с последующим развитием катетер-ассоциированной инфекции кровотока. В статье рассмотрен потенциал нового подхода к профилактике таких осложнений с использованием антимикробного раствора специальной рецептуры (содержащего тауролидин) для закрытия катетера. Принимая во внимание уровень доказательной базы проведённых по этому поводу исследований, а также учитывая собственные данные по чувствительности возбудителей инфекций кровяного русла, авторы приводят фармакодинамическое и фармакокинетическое обоснование более широкого применения данного подхода в клинической практике для установления новых стандартов закрытия катетеров.
-
1.
Eggiman P., Pittet D. Epidemiology and impact of infections associated with use of intravascular devices. In: Seifert H., Jansen B., Farr B.M. editors. Catheter-related infections. 2nd ed. New York: Marcel Dekker; 2004. p.1-22.
-
2.
Richards M., Edwards J., Culver D., et al. Nosocomial infections in medical intensive care units in the United States. NNIS. Crit Care Med 1999; 27:887-92.
-
3.
Mermel L.A., Allon M., Bouza E., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infection diseases society of America. CID 2009; 49:1-45.
-
4.
Бережанский Б.В. Оптимизация фармакотерапии и профилактики инфекций, связанных с центральным венозным катетером в отделениях реанимации и интенсивной терапии. Автореф. дис. канд. мед. наук. Смоленск, 2008. 22с.
-
5.
Sherertz R.G. Pathogenesis of vascular catheter infections. In: Waldvogel F.A., Bisno A.L. editors. Infections associated with indwelling medical devices. 3rd ed. Washington, D.C.: ASM Press; 2000. p.111-25.
-
6.
Raad I. Intravascular-catheter-related infections. Lancet 1998; 351:893-8.
-
7.
Costerton J.W. Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22.
-
8.
Stewart P.S., Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358:135-8.
-
9.
Ceri H., Olson M.E., Stremick C., et al. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilm. J Clin Microbiol 1999; 37:1771-6.
-
10.
Eiff C.V., Heilmann C., Peters G. New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis 1999; 18:843-6.
-
11.
Sherertz R., Ely W., Westbrook D. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med 2000; 132:641-8.
-
12.
Saint S., Savel R., Matthay M. Enhancing the safety of critically patients by reducing urinary and central venous catheter-related infections. Am J Resp Crit Care Med 2002; 165:1475-9.
-
13.
Burn-Busson C. New technologies and infection control practices to prevent intravascular catheter-related infections. Am J Resp Crit Care Med 2001; 164:1557-8.
-
14.
Mermel L. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 133:391-402.
-
15.
De Gaudio A., Di Filippo A. Device-related infections in critically ill patient. Part 1: prevention of catheter-related bloodstream infections. J Chemother 2003; 5:419-27.
-
16.
Gnass S., Barboza L., Bilicich D. Prevention of central venous catheter-related bloodstream infections using non-technologic strategies. Infect Control Hosp Epidemiol 2004; 25:675-7.
-
17.
O'Grady N., Alexander M., Dellenger E., et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2002; 35:1281-307.
-
18.
Collin G. Decreasing catheter colonization through the use of antiseptic-impregnated catheter. Chest 1999; 115:1632-40.
-
19.
Darouiche R. Anti-infective efficacy of silver-coated medical prostheses. Clin Infect Dis 1999; 29:1371-7.
-
20.
Arepally G., Cines D.B. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol 1998; 16:237-47.
-
21.
Elliot T.S.J., Curran A. Effects of heparin and chlorbutol on bacterial colonization of intravascular cannulae in an in vitro model. J Hosp Infect 1989; 14:193-200.
-
22.
Mermel L., Parenteau S. Efficacy of the biolink catheter lock solution for dialock haemodialysis access port and catheters. Infect Control Hosp Epidemiol 2000; 21:86-174.
-
23.
Mermel M.A., Stolz S.M., Maki D.G. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters. J Infect Dis 1993; 167:920-4.
-
24.
Crnich C., Maki D. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. Clin Infect Dis 2002; 34:1362-8.
-
25.
D'Agata E.M.C. Antimicrobial-resistant, gram-positive bacteria among patient undergoing chronic hemodialisis. Clin Infect Dis 2002; 35:1212-8.
-
26.
Centers for disease control and prevention. S. aureus resistant to vancomycin – United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
-
27.
Simon A., Groger N., Wilkesmann A., et al. Restricted use of glycopeptides in paediatric cancer patient with fever and neutropenia. Int J Antimicrob Agents 2006; 28:417- 22.
-
28.
Waser P.G., Sibler E. Taurolidine – a new concept in antimicrobial chemotherapy. In: Harms A.F. editor. Innovative approaches in drug research. Amsterdam: Elsevier Science Publishers B.V.; 1986. p.155-69.
-
29.
Erb F., Imbenotte M., Huveene J. Structural investigation of a new organic antimicrobial: taurolidine analytical study and application to identification and quantitation in biological fluids. Eur J Drug Metab Pharmacokinet 1983; 8:163-73.
-
30.
Gormann S.P., McCafferty D.F., Woolfson A.D., et al. Reduced adherence of micri-organism to human mucosal epithelial cells following treatment with Taurolin®, a novel antimicrobial agent. J Appl Bacteriol 1987; 62:315- 20.
-
31.
Calabresi P., Goulette F.A., Darnowski J.W. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001; 61:6816-21.
-
32.
Willatts S.M. Radford S., Leitermann M. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind study. Crit Care Med 1995; 23:1033-9.
-
33.
Blenkharn J.I. Prevention of septic complications associated with TNP. J Parenter Enter Nutr 1986; 10:436-7.
-
34.
Quarello F., Forneris G. Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock. Blood Purif 2002; 20:87-92.
-
35.
Torres-Viera C., Thauvin-Eliopoulos C., Souli M., et al. Activities of Taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000; 44:1720-4.
-
36.
Mittelman M.W., Pelak M., Shah C., et al. Eradication of microbial biofilms with an antimicrobial catheterlock solution. Proceedings of General meeting of ASM, Chicago, USA, 2001. Abstract.
-
37.
TauroPharm GmbH, Waldbuttelbrunn, data on file.
-
38.
Shah C.B., Mittelman M.W., Costerton J.W., et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002; 46:1674-9.
-
39.
Sherertz R.G., Boger M.S., Collins C.A., et al. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother 2006; 50:1865-8.
-
40.
Sodemann K., Polaschegg H.D., Feldmer B. Two years’ experience with Dialock and CLS (a new antimicrobial lock solution). Blood Purif 2001; 19:251-4.
-
41.
Allon M. Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution. Clin Infect Dis 2003; 36:1539-44.
-
42.
Betjes M.G.H., van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004; 19:1546-51.
-
43.
Jurewitsch B., Jeejeebhoy K.N. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infection. Clin Nutr 2005; 24:462-5.
-
44.
Simon A., Ammann R.A., Wiszniewsky G., et al. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infectious Diseases 2008; 8:102.
-
45.
Koldehoff M., Zakrzewski J.L. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patient. Int J Antimicrob Agents 2004; 24:491-5.